Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov;18(11):2554-2556.
doi: 10.1038/s41423-021-00767-9. Epub 2021 Sep 16.

T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals

Affiliations

T cell immune responses to SARS-CoV-2 and variants of concern (Alpha and Delta) in infected and vaccinated individuals

Stanley C Jordan et al. Cell Mol Immunol. 2021 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Immune responses in SARS-CoV-2-infected patients and vaccinated individuals.
A, B SARS-CoV-2 Spike-specific CD4+ and CD8+ T cells in healthy, infected and vaccinated individuals. Whole blood was stimulated with Spike peptides, and T cells with dual-cytokine staining were gated. The blue line shows the 0.05% cutoff. C The correlation of Nucleocapsid-specific IgG titers with CD4+ T cell immune responses to one or more of 5 major SARS-CoV-2 proteins in 25 patients. D The correlation between Spike-specific CD4+ T cell immune responses and Spike-specific IgG levels in 13 patients with elevated CD4+ Spike-specific T cell immune responses (IL-2+/TNF-α+ cell% in CD4+ >0.3%). E, F T cell immune responses to ancestral and variant spike peptides are shown. CD4+/CD8+ Spike-specific T cells from infected and vaccinated healthy individuals were assessed for reactivity to ancestral, Alpha variant and Delta variant Spike peptides. Each dot represents one individual. *P = NS; ***p < 0.001.

References

    1. Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, et al. SARS-CoV-2 variants and vaccines. N. Engl J Med. 2021;385:179–86. doi: 10.1056/NEJMsr2105280. - DOI - PMC - PubMed
    1. Anand SP, Prévost J, Nayrac M, Beaudoin-Bussières G, Benlarbi M, Gasser R, et al. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. Cell Rep Med. 2021;2:100290. doi: 10.1016/j.xcrm.2021.100290. - DOI - PMC - PubMed
    1. Radbruch A, Chang HD. A long-term perspective on immunity to COVID. Nature. 2021. 10.1038/d41586-021-01557-z. - PubMed
    1. Ratcliff J, Nguyen D, Fish M, Rynne J, Jennings A, Williams S, et al. Virological and serological characterization of critically ill patients with COVID-19 in the UK: Interactions of viral load, antibody status and B.1.1.7 variant infection. J Infect Dis. 2021. 10.1093/infdis/jiab283. - PMC - PubMed
    1. Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S, et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1059–62. doi: 10.15585/mmwr.mm7031e2. - DOI - PMC - PubMed